The life history of 21 breast cancers.
Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, Raine K, Jones D, Marshall J, Ramakrishna M, Shlien A, Cooke SL, Hinton J, Menzies A, Stebbings LA, Leroy C, Jia M, Rance R, Mudie LJ, Gamble SJ, Stephens PJ, McLaren S, Tarpey PS, Papaemmanuil E, Davies HR, Varela I, McBride DJ, Bignell GR, Leung K, Butler AP, Teague JW, Martin S, Jönsson G, Mariani O, Boyault S, Miron P, Fatima A, Langerød A, Aparicio SA, Tutt A, Sieuwerts AM, Borg Å, Thomas G, Salomon AV, Richardson AL, Børresen-Dale AL, Futreal PA, Stratton MR, Campbell PJ, Breast Cancer Working Group of the International Cancer Genome Consortium. · 2012
Read The life history of 21 breast cancers. by Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, Raine K, Jones D, Marshall J, Ramakrishna M, Shlien A, Cooke SL, Hinton J, Menzies A, Stebbings LA, Leroy C, Jia M, Rance R, Mudie LJ, Gamble SJ, Stephens PJ, McLaren S, Tarpey PS, Papaemmanuil E, Davies HR, Varela I, McBride DJ, Bignell GR, Leung K, Butler AP, Teague JW, Martin S, Jönsson G, Mariani O, Boyault S, Miron P, Fatima A, Langerød A, Aparicio SA, Tutt A, Sieuwerts AM, Borg Å, Thomas G, Salomon AV, Richardson AL, Børresen-Dale AL, Futreal PA, Stratton MR, Campbell PJ, Breast Cancer Working Group of the International Cancer Genome Consortium. (2012) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3428864.txt.
Introduction
Nik-Zainal and a large team reconstructed the life histories of twenty-one breast cancers in 2012 from the mutations written into their genomes. A cancer evolves as cell families replace one another under shifting pressures, and the genome keeps the diary. The team built algorithms to read that diary in order.
Mutational processes, they found, change across a cancer's lifespan, with several switching on late yet adding huge variation. Most mutations sit in only a fraction of tumor cells, showing rich branching, but every tumor kept one dominant family making up over half its cells. That family's takeoff seems to need hundreds or thousands of mutations first, and its expansion may be the final step that brings the cancer to notice.
Catalog record
| CREATOR | Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, Raine K, Jones D, Marshall J, Ramakrishna M, Shlien A, Cooke SL, Hinton J, Menzies A, Stebbings LA, Leroy C, Jia M, Rance R, Mudie LJ, Gamble SJ, Stephens PJ, McLaren S, Tarpey PS, Papaemmanuil E, Davies HR, Varela I, McBride DJ, Bignell GR, Leung K, Butler AP, Teague JW, Martin S, Jönsson G, Mariani O, Boyault S, Miron P, Fatima A, Langerød A, Aparicio SA, Tutt A, Sieuwerts AM, Borg Å, Thomas G, Salomon AV, Richardson AL, Børresen-Dale AL, Futreal PA, Stratton MR, Campbell PJ, Breast Cancer Working Group of the International Cancer Genome Consortium. |
|---|---|
| YEAR | 2012 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 72 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The Life History of 21 Breast Cancers By Serena Nik-Zainal, Peter Van Loo, David C. Wedge, Ludmil B. Alexandrov, Christopher D. Greenman, King Wai Lau, Keiran Raine, David Jones, John Marshall, Manasa Ramakrishna, Adam Shlien, Susanna L. Cooke Published in: Cell DOI: 10.1016/j.cell.2012.04.023 ABSTRACT Summary Cancer evolves dynamically as clonal expansions supersede one another driven by shifting selective pressures, mutational processes, and disrupted cancer genes. These processes mark the genome, such that a cancer's life history is encrypted in the somatic mutations present. We developed algorithms to decipher this narrative and applied them to 21 breast cancers. Mutational processes evolve across a cancer's lifespan, with many emerging late but contributing extensive genetic variation. Subclonal diversification is prominent, and most mutations are found in just a fraction of tumor cells. Every tumor has a dominant subclonal lineage, representing more than 50% of tumor cells. Minimal expansion of these subclones occurs until many hundreds to thousands of mutations have accumulated, implying the existence of long-lived, quiescent cell lineages capable of substantial proliferation upon acquisition of enabling genomic changes. Expansion of the dominant subclone to an appreciable mass may therefore represent the final rate-limiting step in a breast cancer's development, triggering diagnosis. PaperClip INTRODUCTION Age-incidence curves of most common epithelial cancers show rapidly increasing rates after the 4th–5th decades of life. Classic mathematical models of tumor development developed by Armitage and Doll (Armitage and Doll, 1954; Hornsby et al., 2007) suggested that 5–8 rate-limiting events are required to generate such incidence patterns. Since these studies were performed in the 1950s, we have learnt much about the biological and genetic basis of cancer. In particular, evolution toward cancer often occurs on a phenotypic spectrum of increasingly disordered premalignant stages, as “hallmark” cellular processes are cumulatively co-opted or ablated in the cancer cells (Hanahan and Weinberg, 2011). Somatic mutation is the fundamental mechanism by which cancer cells suborn these pathways (Stratton et al., 2009), notwithstanding the contributions of epigenetic changes, cues from the local microenvironment and germline genetic variation. Whole-cancer genomes sequenced to date carry thousands to tens of thousands of somatic mutations (Chapman et al., 2011; Ding et al., 2010; Ley et al., 2010; Pleasance et al., 2010a, 2010b; Puente et al., 2011; Shah et al., 2009), the vast majority of which probably have no biological relevance. The accumulation of mutations in cancerous and precancerous cells over time is increasingly recognized as a complex, dynamic process. Carcinogenic exposures and DNA repair defects can lead to sustained elevations in mutation rate; telomere attrition and chromothripsis can drive massive genomic rearrangement in catastrophic bursts (Bignell et al., 2007; Campbell et al., 2010; O'Hagan et al., 2002; Stephens et al., 2011). In the classic view of cancer development, those somatic mutations conferring a selective advantage on the cell drive successive waves of clonal expansion, with the fittest clone coming to dominate the cellular compartment. Increasingly, however, cancers are recognized to be mixtures of competing subclones, based on analyses of cancers sampled within a patient at different times (Ding et al., 2012; Shah et al., 2009), from different sites (Campbell et al., 2010; Ding et al., 2010; Yachida et al., 2010), at hypermutable genomic loci (Campbell et al., 2008), or through single-cell isolation (Anderson et al., 2011; Navin et al., 2011; Notta et al., 2011). Although these studies imply the existence of genetic heterogeneity within a tumor, fundamental questions remain about the dynamics of Darwinian evolution in cancer, the biological relevance of subclonal genetic variation and the relationship between mutational processes and clonal expansion. Here, we use newly developed bioinformatic algorithms (Greenman et al., 2012) to reconstruct the genomic history of 21 breast cancers. Borrowing the concept of a “most-recent common ancestor” from population genetics, we can divide somatic mutations into those acquired before the last complete selective sweep (and thus shared by all cancer cells within the sample) and those subclonal variants that occurred after the emergence of the common ancestor. We study the early genomic evolution of the eventual cancer clone, quantify the extent and dynamics of subclonal variation within the cancer sample sequenced and explore changes in mutation signatures over time. These findings have important implications for our understanding of how breast cancers develop over the decades between breast organogenesis and diagnosis in the adult. RESULTS Inference of Cancer Genome Evolution We sequenced 20 primary breast cancer samples to an average 30–40 coverage across each base in the genome. The sample series includes four cases each of estrogen-receptor (ER)-positive, HER2-positive, and BRCA2-positive breast cancer; three cases of triple negative; and five cases of BRCA1-positive breast cancer. In addition, we sequenced to 188-fold depth one other ER-positive tumor with a distinctive mutator phenotype, consisting of C>A, C>G and C>T mutations specifically in a TpC context. As described in the companion paper to this (Nik-Zainal et al., 2012, this issue of Cell), we identified a high-confidence, validated set of base substitutions, insertions, and deletions (indels); genomic rearrangements; and copy number changes in the 21 cancers. To develop the reasoning that underpins this paper, we start with the tumor sequenced to 188-fold depth, PD4120a. At the chromosomal scale, the cancer genome is hypodiploid, with relatively few copy number changes (Figure 1A). To exploit the considerable sequencing depth available for this tumor, we modified the parameters of our somatic substitution algorithm in order to identify subclonal mutations; those found in only a fraction of tumor cells. In total, we identified 70,690 somatic substitutions genome-wide, including many in which fewer than 5% of the reads across the base reported the variant allele. That these are bona fide mutations is evidenced by the dominance of the C>∗ mutations in a TpC context at all levels of subclonality (Figures S1A and S1B, available online) and a high rate of verification in a subset by targeted PCR and pyrosequencing. The mutations fall into well-circumscribed clusters when displayed by the fraction of reads reporting the variant (Figure 1B and Figure S1C). The major cluster of points occurs at a read depth around 210, with about 35% of reads reporting each variant. Because an estimated 70% of cells in the sample derive from the cancer clone, this cluster represents those point mutations found in all tumor cells on one copy of a diploid chromosome. By comparison, mutations from regions of copy number 1 show a lower overall read depth (because the copy number is lower) but higher variant allele fraction (because there are no reads from the deleted chromosome). The genome has one triploid chromosomal region, 1q, which is most likely to have arisen as a single gain of one whole chromosome arm, although we cannot formally exclude duplication of both alleles with subsequent loss of one. Mutations occurring on the relevant chromosomal arm before duplication would be present on two of three copies (with an expected variant allele fraction of ∼55%), whereas mutations occurring after the duplication would be present on only one copy. In fact, we find only seven mutations on 1q predicted to have occurred before the chromosome arm was duplicated, not one of which has the signature of C>∗ mutations in a TpC context (Figure S1C). In contrast, 1,250 mutations are found on 1q at single copy number, of which 1,130